Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  West Pharmaceutical Services Inc.    WST

Delayed Quote. Delayed  - 09/28 06:49:30 pm
73.4799 USD   -0.04%
09/26 WEST PHARMACEUT : Appoints David A. Montecalvo Senior Vice President..
09/21 WEST PHARMACEUT : Declares Dividend of $0.1300.
09/15 WEST PHARMACEUT : PT Raised to $77.00 at Jefferies Group
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201320142015201620172018
Sales1 3681 4211 4001 5121 6351 750
Operating income (EBITDA)248273280325376416
Operating profit (EBIT)162183190224271311
Pre-Tax Profit (EBT)------
Net income11212795,6154198236
P/E ratio31,230,446,337,127,823,7
EPS ( $ )1,571,751,301,982,643,10
Dividend per Share ( $ )0,390,410,460,490,530,58
Yield0,79%0,77%0,76%0,67%0,72%0,79%
Reference price ( $ )49.0653.2460.2273.5173.5173.51
Announcement Date02/20/2014
12:00pm
02/19/2015
12:00pm
02/18/2016
12:00pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201320142015201620172018
Debt---36,03,807,30
Finance------
Operating income (EBITDA)248273280325376416
Leverage
(Debt/EBITDA)
---0,11x0,01x0,02x
Capital Expenditure--132162158155
Book Value Per Share (BVPS)--14,2 $15,7 $17,2 $18,9 $
Cash Flow per Share3,09 $2,51 $2,88 $3,04 $3,93 $4,42 $
Announcement Date02/20/2014
12:00pm
02/19/2015
12:00pm
02/18/2016
12:00pm
---
Balance Sheet Analysis
Assessed data source :
© 2016 Thomson Reuters
Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 5 382 M$ -
Entreprise Value (EV) 5 418 M$ 5 386 M$
Valuation 2016e 2017e
P/E ratio (Price / EPS) 37,1x 27,8x
Capitalization / Revenue 3,56x 3,29x
EV / Revenue 3,58x 3,29x
EV / EBITDA 16,7x 14,3x
Yield (DPS / Price) 0,67% 0,72%
Price to book (Price / BVPS) 4,69x 4,27x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 14,8% 16,6%
operating Leverage (Delta EBIT / Delta Sales) 2,26x 2,54x
Net Margin (Net Profit / Revenue) 10,2% 12,1%
ROA (Net Profit / Asset) 8,30% 10,6%
ROE (Net Profit / Equities) 14,0% 15,7%
Rate of Dividend 24,7% 20,1%
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   10,7% 9,68%
Cash Flow / Sales 14,7% 17,6%
Capital Intensity (Assets / Sales) 1,23x 1,14x
Financial Leverage (Net Debt / EBITDA) 0,11x 0,01x
Price Earning Ratio Help 
The blue ligne is the average P/E ratio (without estimates)
EPS & Dividend